Arno Therapeutics Reports First Quarter 2016 Financial And Business Update
FLEMINGTON, N.J., May 16, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended March 31, 2016 and provided an update on recent clinical developments for its lead compound, onapristone.
Q1 2016 and Recent Highlights:
* Continued to actively enroll patients in the second stage of its Phase I/II trial of onapristone in men with advanced, castration-resistant prostate cancer (CRPC) who have failed treatment with abiraterone or enzalutamide. The Phase II portion of this study will evaluate onapristone in combination with Zytiga® (abiraterone acetate) in patients with CRPC.
Q1 2016 and Recent Highlights:
* Continued to actively enroll patients in the second stage of its Phase I/II trial of onapristone in men with advanced, castration-resistant prostate cancer (CRPC) who have failed treatment with abiraterone or enzalutamide. The Phase II portion of this study will evaluate onapristone in combination with Zytiga® (abiraterone acetate) in patients with CRPC.